Navigation Links
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Date:6/20/2013

SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, ILAbstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
2. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
3. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
5. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
6. Orexigen Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
10. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
11. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Epic Sciences announced ... sequencing data, from metastatic castrate resistant prostate cancer ... American Society for Clinical Oncology. This application expands ... cell left behind™ platform to characterize circulating ... that late stage patients have heterogeneous clonal CTC ...
(Date:5/29/2015)... Calif. , May 29, 2015 ... data from two pivotal Phase 3, global, randomized, ... for the treatment of secondary hyperparathyroidism (SHPT) in ... Both studies met the primary endpoint, demonstrating that ... 416 groups achieved a greater than 30 percent ...
(Date:5/29/2015)... MALVERN, Pa. , May 29, 2015 /PRNewswire-USNewswire/ ... major focus of the Association for the Advancement ... 1995. With support from AAWC,s corporate ... Educational Portal on the AAWC website ... on a wound care pathway with links to ...
Breaking Medicine Technology:Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7The Association for the Advancement of Wound Care Educates the Public 2
... Nov. 16, 2010 Questcor Pharmaceuticals, Inc. (Nasdaq: ... Maxim Group Growth Conference at 4:00 p.m. ET on Thursday, ... York. Don M. Bailey, President and Chief Executive Officer, will ... Attendance at this conference is by invitation only. A ...
... Eli Lilly and Company (NYSE: LLY ) ... compound patent for Alimta® (pemetrexed for injection) before the U.S. ... with a ruling from the court that judgment would be ... decision came in the case of Eli Lilly and ...
Cached Medicine Technology:Questcor to Present at the Maxim Group Growth Conference 2U.S. District Court Rules from Bench in Lilly's Favor, Confirms Validity of Alimta Patent 2
(Date:5/30/2015)... (PRWEB) May 30, 2015 The IRS ... 26th 2015, announcing that, “criminals used taxpayer-specific data acquired ... on approximately 100,000 tax accounts through IRS’ “Get Transcript” ... birth and street address.” , “You don’t even ... have to think it was only a matter of ...
(Date:5/29/2015)... 30, 2015 “In the current ... and federal regulations, we provide education that will ... who are suffering from pain, within the boundaries ... MD, professor of rehabilitation medicine and President/Medical Director ... Park, Kansas. , A new flight of PAINWeekEnd ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 Ready to ... it’s important for all drivers to get their vehicles ready. ... to be prepared. Advanced Driving Systems (ADS) is ready to ... tips on preparing for summer road trips. , When planning ... the following to ensure that the trip goes smoothly and ...
(Date:5/29/2015)... The science of hair restoration has taken ... the efforts of internationally recognized hair transplant surgeon Dr. ... hair restoration and manual FUE techniques to offer ... , A Follicular Unit Extraction (FUE) is ... grafts from the donor areas of a patient. ...
(Date:5/29/2015)... The third annual Newport 10 Miler kicks ... new registration, starts outside the east wall of National ... event demonstrates the power of combining professional event management ... in this case, historic preservation. , The course ... Drive and passes by many Bellevue Avenue mansions. The ...
Breaking Medicine News(10 mins):Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 2Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 3Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 4Health News:IRS Attack Exemplifies the Compounding Dangers of Stolen Personal Data 5Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3
... The International AIDS Society is grossly disappointed with the UN ... to facilitate all the earmarked prevention programs needed to battle ... of The International AIDS Society said 'The lack of clear ... of health workers we need in order to deliver prevention ...
... Indian biotech sector, the western region has claimed the ... by contributing 50 percent of the total revenues of ... the southern region. ,Giving an account of the ... Mazumdar-Shaw told the Bangalore Bio 2006 event here Wednesday ...
... Rajasthan man who has pledged not to marry till he passes ... a wife. He has failed in the examination yet again! // ... Behror town, over 140 km from here, has been taking the ... years of his life, he vowed to marry only after getting ...
... success of every person whether to be self-employed or not ... background and grown environment comparatively have lesser effect than genes ... of twins shows. It was also proved to be true ... College, London, and Case Western Reserve University in Cleveland, US. ...
... authorities of central Illinois they are going through a period of ... in the month of July and results in a couple of ... deaths crossed 66. But due to various precautionary measures and other ... reduced to 12 in 2005. It is mainly transmitted by a ...
... elderly people have died after an outbreak of tuberculosis at ... the fourth resident at the home is recovering after being ... NHS Lanarkshire said that four residents of the Eastercroft House ... three of those residents also had other long-standing medical problems ...
Cached Medicine News:Health News:Western Region Tops in Indian Biotech Growth 2